Table 3.

Correlation of bone formation and resorption markers (absolute change) after 3 months and BMD measured at lumbar spine and hip (percentage change) after 6 and 12 months of follow-up

	BMD lumbar spine, 6 months	BMD hip, 6 months	BMD lumbar spine, 12 months	BMD hip, 12 months
P1NP control	−0.388 [0.167]	−0.484 a[0.022]	−0.010 [1.000]	−0.214 [1.000]
P1NP denosumab	−0.293 [0.966]	−0.046 [1.000]	−0.240 [1.000]	+0.042 [1.000]
BSAP control	−0.506a[0.013]	−0.476a[0.026]	−0.075 [1.000]	−0.238 [1.000]
BSAP denosumab	−0.258 [1.000]	−0.035 [1.000]	−0.128 [1.000]	−0.026 [1.000]
DPDb control	−0.476 [0.075]	−0.296 [1.000]	−0.212 [1.000]	−0.160 [1.000]
DPDb denosumab	−0.363 [0.561]	−0.209 [1.000]	−0.376 [0.524]	−0.156 [1.000]
β-CTX control	−0.298 [0.769]	−0.408 [0.116]	−0.040 [1.000]	−0.121 [1.000]
β-CTX denosumab	−0.102 [1.000]	−0.104 [1.000]	−0.115 [1.000]	−0.203 [1.000]
PTH control	+0.129 [1.000]	+0.103 [1.000]	−0.102 [1.000]	+0.010 [1.000]
PTH denosumab	+0.076 [1.000]	+0.162 [1.000]	−0.330 [0.627]	−0.082 [1.000]

Data depicted as Spearman's rho [p value]. P1NP, procollagen-1 N-terminal propeptide; BSAP, bone-specific alkaline phosphatase; DPD, urine deoxypyridinoline/Cr; β-CTX, β-isomer of C-terminal telopeptide of type I collagen; PTH, parathyroid hormone.

^aSignificance met by p ≤ 0.05 (p values are Holm corrected within the treatment group).

^bDPD had up to 15% missing values and in consequence even moderate correlations did not prove to be significant.